Multisite, open-label, prospective trial of lamotrigine for geriatric bipolar depression: A preliminary report

Department of Psychiatry, Case Western Reserve University School of Medicine, University Hospitals Case Medical Center, Cleveland, OH, USA.
Bipolar Disorders (Impact Factor: 4.97). 05/2011; 13(3):294-302. DOI: 10.1111/j.1399-5618.2011.00923.x
Source: PubMed


This is a multisite, 12-week, open-label trial of lamotrigine augmentation in 57 older adults (≥ 60 years; mean ± SD age = 66.5 ± 6.7 years) with either type I or type II bipolar depression.
Primary outcome measure was change from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS). Secondary outcome measures included Hamilton Depression Rating Scale (HAM-D), Clinical Global Impression-Bipolar version (CGI-BP), and the WHO-Disability Assessment Schedule II (WHO-DAS II). The Udvalg for Kliniske Undersøgelser (UKU) was used to assess side effects.
A total of 77.2% of the study subjects had bipolar I disorder. The mean (SD) lamotrigine dose was 150.9 (68.5) mg/day. There was significant improvement in the MADRS, HAM-D, CGI-BP, and in most domains on the WHO-DAS II. For patients for whom final MADRS score was available: 31 (57.4%) met remission criteria and 35 (64.8%) met response criteria. There were 19/57 (33.3%) who dropped out of the study prematurely, with 6 dropouts due to adverse events (4 cases of rash, 1 manic switch, and 1 hyponatremia). Two cases of rash were possibly drug related and were resolved with drug discontinuation. The most common UKU adverse effects were reduced sleep duration (n = 14, 24.6%), weight loss (n = 12, 21.1%), increased dream activity (n = 12, 21.1%), polyuria/polydipsia (n = 11, 19.3%), weight gain (n = 9, 15.8%), diminished sexual desire (n = 9, 15.8%), increased sleep (n = 9, 15.8%), lassitude/fatigue (n = 8, 14%), and unsteady gait (n = 8, 14%). No significant changes in electrocardiogram or laboratory tests were observed.
In bipolar depressed elders, lamotrigine was associated with improvement in depression, psychopathology, and functional status. There was a moderate number of adverse events, although relationship of adverse events (particularly falls) to study medication could not be clearly determined in this uncontrolled trial. Controlled studies are needed to further evaluate efficacy and tolerability of lamotrigine therapy in geriatric bipolar depression.

8 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The use of lithium carbonate for the treatment of bipolar disorder in older adults is decreasing at a significant rate. This change in prescription pattern is occurring at a time when all evidence-based treatment guidelines and systematic reviews still recommend lithium as a first-line treatment for bipolar disorder. Despite having the strongest evidence base for effectiveness, lithium does pose significant concerns in the older population, including the risk of drug interactions that cause toxicity associated with decreased creatinine clearance. The evidence for lithium's impact on chronic renal disease is still controversial and is reviewed in this article. Mixed evidence exists regarding the impact of lithium on suicide risk, although there is a consensus that it does have protective properties through its mood-stabilizing effect. Because of the very limited research base regarding the use of lithium in old age, guidelines for dosing and maintenance of serum concentrations are not well established, and this may be leading to increased episodes of lithium toxicity. At the same time that these legitimate concerns about lithium are being highlighted, evidence has accumulated that suggests that lithium may have neuroprotective properties. Its action of inhibiting the enzyme glycogen synthase kinase-3 may be responsible in part for a decrease in the induction of amyloid beta peptide and hyperphosphorylated tau protein, which have been implicated in the development of Alzheimer's disease. Very little evidence supports use of alternatives to lithium such as other mood-stabilizing agents, including atypical antipsychotics, in older adults. Thus, before we abandon lithium as a first-line agent, we should ensure that the guidelines for lithium treatment are safe, practical and effective. Newer agents must be appropriately tested in older adults before replacing this longstanding first-line treatment for bipolar disorder.
    Drugs & Aging 08/2010; 27(8):607-15. DOI:10.2165/11537700-000000000-00000 · 2.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Over 1200 participants from a wide array of psychogeriatric disciplines attended the 15th world congress of the International Psychogeriatric Association (IPA) in The Netherlands. In previous years, the meetings and activities of the IPA were strongly focused on research restricted to diagnosis and care of individuals with dementia. In recent years, there has been a shift of attention towards other psychiatric disorders in the elderly such as schizophrenia, substance abuse and bipolar disorder, which were for a long time nearly invisible in the scientific literature. The symposium venue was located in The Hague, a typical Dutch town not far from the coastline and home to several famous international institutions in the field of peace and justice. This successful meeting with the theme 'Reinventing Aging through Innovation, Care, Research, Technology' was co-chaired by Anne Margriet Pot (Professor of Geropsychology, Amsterdam, The Netherlands) and Frans Verhey (Professor of Neuropsychiatry, Maastricht, The Netherlands). A special symposium on 'Bipolar Disorder in the Elderly' also took place during the 4-day meeting. This symposium was organized by The Netherlands Psychiatric Association, Faculty of Old Age Psychiatry and is an example of a neglected topic in geriatric mental health and represents the important diverse mental disorders that a large proportion of older adults and their families can experience. The symposium was co-chaired by Max Stek, Professor of Old Age Psychiatry and Chair of the Dutch Faculty of Old Age from The Netherlands and Martha Sajatovic from the USA. Presenting faculty were Ralph Kupka and Annemiek Dols from The Netherlands and Lars Kessing from Denmark.
    Aging Health 12/2011; 7(6):797-800. DOI:10.2217/ahe.11.75
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To identify baseline clinical factors associated with acute treatment response in depressed older adults with bipolar disorder (BD) receiving lamotrigine. Secondary analysis of a multisite, 12-week, open-label, uncontrolled study of add-on lamotrigine in 57 adults 60 years and older with BD I or II depression. Measures included the Montgomery Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS). Cardiometabolic risk was measured with total serum cholesterol and the Cumulative Illness Rating Scale-Geriatric (CIRS-G) item #13 (endocrine/metabolic burden). Neurocognitive (executive) function was evaluated using the Trail Making Test. Greater reduction in MADRS from baseline was associated with higher baseline cardiometabolic burden at 6 and 9 weeks and lower YMRS scores at 9 weeks. At 12 weeks, improvement in the MADRS from baseline was no longer significantly related to baseline cardiometabolic burden or YMRS scores. A longitudinal mixed model of MADRS scores corroborated these findings with a significant finding of time-by-baseline cholesterol level interaction. In a subset of participants, better baseline executive function was related to greater improvement in the MADRS at 9 weeks but not at 6 or 12 weeks. Among all participants, higher baseline YMRS scores were related to greater likelihood of dropout. Lamotrigine appears to work best in depressed elderly patients with BD who have high cardiometabolic risk and low level of mania. Agents like lamotrigine that act primarily on neuroprogressive pathways involving oxidative stress, neurotrophins, and inflammation may be particularly effective in individuals with BD who have significant cardiometabolic burden because of their effects on shared vulnerability factors in BD and medical illness.
    Journal of Geriatric Psychiatry and Neurology 03/2012; 25(1):37-42. DOI:10.1177/0891988712436685 · 2.24 Impact Factor
Show more